MSMridula Dhanapal Saravanan

Mridula Dhanapal Saravanan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mridula Dhanapal Saravanan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Phytochemical and Structural Characterization of Powder and Ethanolic Extract of Hedyotis diffusa

    by Kaniga Pandi, Nimithasree Keerthivasan, Mridula Dhanapal Saravanan, Dhanavarsha Govindaraj

    The present investigation focuses on the comparative phytochemical and structural evaluation of Hedyotis diffusa in powder form and its ethanolic extract. A combination of phytochemical screening and analytical techniques, namely Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and scanning electron microscopy (SEM), was utilized to examine their chemical composition and surface characteristics. FTIR analysis revealed the presence of important functional groups, including hydroxyl, carbonyl, and phenolic constituents, as indicated by prominent absorption bands at 3400 cm–1 (O–H stretching), 1635 cm–1 (C=O stretching), and 1050 cm–1 (C–O stretching). These groups are associated with potential involvement in metal ion interaction and stabilization mechanisms. The XRD pattern of the powdered sample exhibited well-defined diffraction peaks, confirming its semi-crystalline structure, while the ethanolic extract showed a predominantly amorphous profile due to the abundance of organic compounds. SEM observations indicated an irregular and finely textured surface morphology, which may contribute to increased surface activity. The comparative findings underscore notable differences between the two forms, offering valuable insight into their physico-chemical and functional properties.

  • Engineering Peptides for Oral Delivery: Structural Design, Barrier Modulation, and Emerging Therapeutic Technologies

    by Renukadevi Jeyavelkumaran, Shakthi Harikrishnan, Mridula Saravanan Dhanapal, Nimithasree Keerthivasan, Sanjay Valliappan

    Oral delivery of peptide therapeutics remains a major challenge due to extensive enzymatic degradation, mucus entrapment, limited epithelial permeability, active efflux, and hepatic first‐pass metabolism, all of which restrict systemic exposure. Recent advances in nanocarrier engineering and AI‐driven design are beginning to overcome these barriers through synergistic innovations in medicinal chemistry, formulation science, and clinically validated enhancer platforms. Mechanistic insights into gastrointestinal physiology have enabled the rational development of technologies such as SNAC and TPE, supporting gastric or intestinal transcellular uptake and establishing the first clinically approved oral peptide formulations. Parallel progress in peptide engineering including cyclization, D‐amino acid substitution, lipidation, and transporter‐targeted conjugation enhances proteolytic stability and epithelial interaction, while next‐generation polymer–lipid hybrids, mucus‐penetrating carriers, bile‐acid–guided systems, and stimuli‐responsive biomaterials provide tunable protection and controlled release across the GI tract. Device‐assisted platforms such as LUMI, SOMA, and RaniPill further expand this toolkit by bypassing epithelial barriers altogether. These technological gains intersect with sustainable manufacturing and green bioprocessing considerations essential for scalable clinical translation, along with persistent global health challenges in LMIC settings. Collectively, these developments highlight a decisive shift toward clinically viable, patient‐centric oral peptide therapeutics and outline a forward SDG‐aligned trajectory in which computational design, eco‐efficient production, and advanced biomaterial systems converge to enable reliable systemic and local delivery via the oral route.